

# Nepal

Population 2018

28 million

Estimates of TB burden <sup>o</sup> , 2018	Number (thousands)	Rate (per 100 000 population)
Total TB incidence	42 (37–48)	151 (133–170)
HIV-positive TB incidence	0.38 (0.32–0.45)	1.4 (1.1–1.6)
MDR/RR-TB incidence <sup>oo</sup>	1.4 (0.77–2.3)	5 (2.8–8)
HIV-negative TB mortality	5.4 (3.8–7.3)	19 (13–26)
HIV-positive TB mortality	0.093 (0.071–0.12)	0.33 (0.25–0.42)

## Estimated proportion of TB cases with MDR/RR-TB, 2018

New cases	2.2% (1.1–3.6)
Previously treated cases	15% (9.6–22)

## TB case notifications, 2018

Total new and relapse	31 855
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	69%
- % pulmonary	71%
- % bacteriologically confirmed <sup>ooo</sup>	80%
- % children aged 0-14 years	5%
- % women	34%
- % men	61%
Total cases notified	32 474

## Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2018	75% (67–85)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2018	13% (9–18)

## TB/HIV care in new and relapse TB patients, 2018

	Number	(%)
Patients with known HIV status who are HIV-positive	200	<1%
- on antiretroviral therapy	190	95%

## Drug-resistant TB care, 2018

% of bacteriologically confirmed TB cases tested for rifampicin resistance <sup>ooo</sup>	
- New cases	50%
- Previously treated cases	56%
Laboratory-confirmed cases*	MDR/RR-TB: 669, XDR-TB: 29
Patients started on treatment**	MDR/RR-TB: 400, XDR-TB: 20
MDR/RR-TB cases tested for resistance to second-line drugs	412

## Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2017	91%	31 219
Previously treated cases, excluding relapse, registered in 2017	81%	425
HIV-positive TB cases registered in 2017	83%	121
MDR/RR-TB cases started on second-line treatment in 2016	68%	348
XDR-TB cases started on second-line treatment in 2016	61%	18

## TB preventive treatment, 2018

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	9.4% (8.6–10)

## TB financing, 2019

National TB budget (US\$ millions)	20
Funding source: 39% domestic, 38% international, 24% unfunded	

<sup>o</sup> Ranges represent uncertainty intervals

<sup>oo</sup> MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin


<sup>ooo</sup> Calculated for pulmonary cases only

\* Includes cases with unknown previous TB treatment history

\*\* Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed


# Tuberculosis profile

(Rate per 100 000 population per year)




Legend:  
■ Total TB incidence  
■ New and relapse TB cases notified  
■ HIV-positive TB incidence

(Rate per 100 000 population per year)




Legend:  
■ HIV-negative TB mortality

## Notified cases by age group and sex, 2018




Legend:  
■ Females ■ Males  Incidence

Treatment success rate (%)



Legend:  
■ New and relapse  
■ Retreatment, excluding relapse  
■ HIV-positive ■ MDR/RR-TB ■ XDR-TB

Total budget (US\$ millions)



Legend:  
■ Unfunded  
■ Funded internationally  
■ Funded domestically